These findings were confirmed using tissue from patients with refractory cancer and a history of immunotherapy, demonstrating that elevated serum GDF-15 concentrations (>1500 pg/ mL3) are associated with decreased cytotoxic CD3+ granzyme B+ T-cell density and proliferating CD3+Ki67+ T-cell density in the tumour. Here, GDF15 is linked to neoplasm.